Melt Pharmaceuticals

United States Founded: 2018 • Age: 8 yrs Acquired By Harrow
Pharmaceutical solutions are developed by Melt Pharmaceuticals in the US.
Request Access

About Melt Pharmaceuticals

Melt Pharmaceuticals is a company based in United States founded in 2018 was acquired by Harrow in September 2025.. Melt Pharmaceuticals has raised $77.29 million across 3 funding rounds from investors including Harrow. Melt Pharmaceuticals offers products and services including MELT-300 and Combination Drug Formulations.

  • Headquarter United States
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Melt Pharmaceuticals, Inc
Operational Areas
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $77.29 M (USD)

    in 3 rounds

  • Latest Funding Round
    $24 M (USD), Series B

    Apr 02, 2024

  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Harrow

    (Sep 26, 2025)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Melt Pharmaceuticals

Melt Pharmaceuticals offers a comprehensive portfolio of products and services, including MELT-300 and Combination Drug Formulations. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

A sublingual tablet is developed for needle- and opioid-free procedural sedation and analgesia in short-duration medical procedures

Non-intravenous and non-opioid sedation formulations are created to address sedation needs in outpatient settings

Funding Insights of Melt Pharmaceuticals

Melt Pharmaceuticals has successfully raised a total of $77.29M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $24 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Series B — $24.0M
  • First Round

    (05 Feb 2019)

  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
Apr, 2024 Amount Series B - Melt Pharmaceuticals Valuation

investors

Jul, 2023 Amount Series B - Melt Pharmaceuticals Valuation

investors

Feb, 2019 Amount Series A - Melt Pharmaceuticals Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Melt Pharmaceuticals

Melt Pharmaceuticals has secured backing from 1 investor. Prominent investors backing the company include Harrow. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Investor Description Founded Year Domain Location
Ophthalmic products marketing services are provided by Harrow.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Melt Pharmaceuticals

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Melt Pharmaceuticals

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Melt Pharmaceuticals Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Melt Pharmaceuticals

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Melt Pharmaceuticals

Frequently Asked Questions about Melt Pharmaceuticals

When was Melt Pharmaceuticals founded?

Melt Pharmaceuticals was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is Melt Pharmaceuticals located?

Melt Pharmaceuticals is headquartered in United States.

Is Melt Pharmaceuticals a funded company?

Melt Pharmaceuticals is a funded company, having raised a total of $77.29M across 3 funding rounds to date. The company's 1st funding round was a Series A of $11M, raised on Feb 05, 2019.

What does Melt Pharmaceuticals do?

Melt Pharmaceuticals was founded in 2018 and is headquartered in the United States. Operations are centered in the pharmaceutical sector, though specific services and products remain undisclosed in available records. The companys domain, meltpharma.com, serves as its online presence. Limited public data exists on detailed activities, with focus inferred on drug development or related innovations typical to the industry.

What products or services does Melt Pharmaceuticals offer?

Melt Pharmaceuticals offers MELT-300 and Combination Drug Formulations.

Who are Melt Pharmaceuticals's investors?

Melt Pharmaceuticals has 1 investor. Key investors include Harrow.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available